Sun Jan 2 22:22:56 2022
(*0bc15a9d*):: +public!
I have been looking at the quick New therapies for Covid. **the real Monsters are coming**.
Partnerships are key to our innovation
In June 2019, we announced a five-year collaboration with the University of California to establish a state-of-the-art laboratory for _CRISPR_ technologies, establishing the Laboratory for Genomics Research (LGR)
With a focus on immunology, oncology and neuroscience, the new laboratory will explore how gene mutations cause disease and develop new technologies using CRISPR, the most powerful tool in functional genomics, to rapidly accelerate the discovery of new medicines. GSK’s artificial intelligence and machine learning group will be involved in building the necessary computational pipelines to analyse the data.
The LGR aims to automate existing CRISPR approaches so that this work can be done at scale. Ultimately the goal is to deepen our understanding of genetics and discover new targets, and to create next generation technologies that will become future standard practice for the pharmaceutical industry.
In 2018, we formed an exclusive collaboration with **23andMe** the world’s leading consumer genetics and research company. This collaboration combines our scientific and medical knowledge with 23andMe’s large-scale genetic resources and unique data science skills, improving the probability of R&D success
Other strategic partnerships include: Altius Institute, which pioneers new technologies and approaches for decoding gene control; the UK Biobank, which is generating anonymised genetic sequence data from 500,000 volunteers, and the **Open Targets consortium**, which supports an open access search engine that searches, evaluates and integrates biologic and genetic disease data. +public!
*** Research | GSK
*** Our research is focused on science related to the immune system, the use of human genetics, and the application of advanced technologies.
*** gsk.com
